I was going to address this pre-emptively but then didn't want to complicate things unncessarily.

Since you mentioned, yes most people with diabetes die from CVD and that's why a lot of treatments try to reduce morbidity / mortality associated CVD not just lowering blood sugar level in patients with diabetes.

RVX trial did just that, i.e. trying to reduce composite endpoints for CVD in patients with diabetes.

I didn't read the EMPEROR trial, but I bet some patients had diabetes on top of heart failure.

Yes, these heart failure and didabetes can co-exist in patients but main inclusion criteria for BOM trial is diabetes plus CVD and those for EMPEROR trial is heart failure plus/minus other comorbidities.

Plus, BOM1 trial primary endpoint didn't meet statistical significance (DM should also be clear abt this on his slide).